CROSS-FILE ANALYSIS
Compare the outcome maps
The mechanisms differ. The measured outcomes differ. Evidence maturity differs most.
In plain English
These three peptides do different jobs. Semaglutide changes appetite, blood-sugar signaling, and food intake through the GLP-1 receptor. Tesamorelin prompts the pituitary to release growth hormone, then works through the GH–IGF-1 axis. MOTS-c is a mitochondrial signal studied for cellular stress and muscle energy handling.
Their evidence is also at different stages. Semaglutide has large human trials with weight, cardiovascular, and kidney outcomes [2][3][4]. Tesamorelin has randomized human trials focused on visceral fat and body composition in adults with HIV-associated lipodystrophy [6][8][10][11]. MOTS-c has detailed cell and animal work, plus observational human data, but no human efficacy trial in this source set [13][14][16][17].
The comparison is therefore an evidence map, not a winner board. The useful question is which outcome each program measured, in which population, and at what level of certainty.
The matrix
| Compound | Primary system | Direct human intervention evidence | Functional-outcome emphasis | Main boundary |
|---|---|---|---|---|
| Semaglutide | GLP-1 receptor | Large randomized trials | Body weight; cardiovascular and kidney events | Lean tissue and mobility are not resolved by scale weight |
| Tesamorelin | Pituitary GHRH receptor; GH–IGF-1 axis | Randomized trials in HIV-associated lipodystrophy | Visceral fat, liver fat, trunk fat, lean mass | Population does not establish general-obesity effects |
| MOTS-c | Mitochondrial stress signaling; AMPK and CK2 pathways | No efficacy trial in this source set | Mouse muscle glucose uptake, atrophy, grip, gait, running | Preclinical function cannot be translated into human benefit |
Mechanism is not an outcome
Semaglutide’s mechanism predicts lower intake through appetite and satiety pathways. Trials confirm a large average weight effect and extend the file to cardiovascular and kidney outcomes [2][3][4]. The mature evidence connects receptor action to measured human events.
Tesamorelin’s mechanism predicts GH–IGF-1 activation and lipolysis. Imaging trials then show changes in visceral and liver fat, while pooled data show higher lean body mass [6][8]. Here, the mechanism and tissue measures align closely.
MOTS-c has a strong mechanistic story. It enters the nucleus under metabolic stress, regulates stress-response genes, and directly binds CK2 in experimental systems [13][17]. Mouse function improved in several tests [16]. The missing link is a human intervention trial. A plausible mechanism cannot fill that gap.
Body weight versus body composition
Semaglutide has the clearest body-weight result. STEP 1 reported mean change of −14.9% at 68 weeks, compared with −2.4% for placebo [4]. That is a strong scale-weight result. It is not a complete body-composition analysis.
Tesamorelin produces a different record. Across five randomized trials, visceral fat, trunk fat, and hepatic fat declined while lean body mass increased [6]. The pivotal studies were not designed as routine obesity trials. They were conducted in HIV-associated lipodystrophy. Still, they show why two interventions can affect “weight” through very different tissue patterns.
MOTS-c has no demonstrated human body-weight or body-composition effect in this corpus. Mouse work on atrophy and glucose uptake generates hypotheses about muscle function [13]. It does not supply a human estimate.
Mobility and energy measures
MOTS-c owns the most explicit movement outcomes: treadmill performance, grip strength, and gait in mice [16]. Semaglutide and tesamorelin pages center on human clinical events or tissue composition, not direct mobility tests in the cited source set.
That does not make the MOTS-c evidence stronger. Directness of outcome and maturity of evidence are separate axes. A mouse gait result can be functionally relevant and clinically unproven at the same time. A cardiovascular-event result can be clinically decisive while saying little about strength.
Energy language also needs discipline. Semaglutide mainly reduces intake. Tesamorelin promotes lipolysis through GH–IGF-1 signaling. MOTS-c is tied to AMPK, purine metabolism, mitochondrial stress signaling, and skeletal muscle. “Energy” therefore means three different biological records, not a shared sensation or promised effect.
Safety and evidence maturity
Semaglutide has the broadest safety file in this set. Gastrointestinal effects and biliary disease are established concerns; rare pancreatic and thyroid-cancer signals remain unresolved [5]. Its scale and maturity allow risks to be characterized more clearly.
Tesamorelin’s controlled trials support its approved HIV-lipodystrophy indication, and LiverTox considers clinically apparent liver injury unlikely [7]. GH–IGF-1 activation still creates specific cautions, while evidence outside the approved population remains limited. Visceral fat also reaccumulates after discontinuation [10].
MOTS-c has the greatest uncertainty. Lack of human efficacy trials also means lack of a clinical safety profile. No clean comparison of adverse-event rates is possible. Unknown does not mean safe or unsafe. It means unmeasured.
Read the outcome before the headline
A useful comparison begins with four checks: species, study design, population, and endpoint. Semaglutide’s large human event trials answer questions that animal studies cannot [2][3]. Tesamorelin’s imaging trials isolate fat compartments that total weight obscures [6][8]. MOTS-c experiments probe muscle and stress pathways with a depth not yet matched by human intervention data [13][16][17].
No single measure settles metabolic function. Body weight can fall while lean tissue changes. Visceral fat can change without a dramatic scale shift. Mouse performance can improve without a proven human therapy. The strongest conclusion is the bounded one.